Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proscavax (OncBioMune Pharmaceuticals, Inc.)
- Development stage
- Unknown
- Lead developer
- OncBioMune Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Proscavax is a therapeutic cancer vaccine developed by OncBioMune Pharmaceuticals for the treatment of prostate cancer. The vaccine is a combination product consisting of the prostate-specific antigen (PSA) as the target antigen, along with two cytokines, Interleukin-2 (IL-2) and Granulocyte-macrophage colony-stimulating factor (GM-CSF), which serve as biological adjuvants to enhance the immune response. Proscavax is designed to stimulate the patient's immune system to recognize and eliminate PSA-expressing malignant cells. It has been evaluated in Phase 2 clinical trials for patients with localized prostate cancer, particularly those under active surveillance, to determine its efficacy in slowing disease progression and increasing PSA doubling time.
- Brand names
- Proscavax
- Other names
- PSA/IL-2/GM-CSF vaccineprostate-specific antigen + interleukin-2 + granulocyte-macrophage colony-stimulating factor
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)PSA (Puromycin-sensitive aminopeptidase)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on Proscavax (OncBioMune Pharmaceuticals, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proscavax (OncBioMune Pharmaceuticals, Inc.).